(Q46066416)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

L Amler

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

18 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

535-538

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

Genome-wide association studies for common diseases and complex traits

23 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Clinical proteomics: Written in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.9

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2009.9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19295504%20AND%20SRC:MED&resulttype=core&format=json

release_jaybxu7odfg6jga2jjmv4wleei

23 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jaybxu7odfg6jga2jjmv4wleei

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference